updated 9/17/2010 1:46:02 PM ET 2010-09-17T17:46:02

NEW YORK, Sept. 17, 2010 (GLOBE NEWSWIRE) -- Sarraf Gentile LLP announces that it is investigating Arena Pharmaceuticals, Inc. ("Arena" or the "Company) (Nasdaq:ARNA) in connection with the rejection of the Company's weight loss pill lorcaserin by a panel of Food and Drug Administration experts.

According to the Associated Press, an FDA panel of experts voted 9-5 on Thursday, September 16, 2010, against the approval of lorcaserin saying some unresolved safety questions outweighed its benefits and raising concerns about tumors seen in rats in early-stage testing. The Company's share fell 45% percent, or $1.67, to $2.08 in trading Friday before the market opened, according to the Associated Press.

If you purchased or own Arena stock and want to discuss your legal rights, at no cost and without obligation, please contact Joseph Gentile at Sarraf Gentile LLP (telephone: 212-868-3610; e-mail: joseph@sarrafgentile.com ). 

Sarraf Gentile LLP has extensive experience litigating shareholder class actions across the United States and has recovered millions of dollars on behalf of injured shareholders. 

ATTORNEY ADVERTISING. Prior results do not guarantee a similar outcome.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com